Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
- Significant improvements in neuromuscular and respiratory function at 24-week timepoint- Encouraging initial efficacy observed at four-week timepoint in Cohort 1 expansion patients- Patient 1 has ac...
Page (1) of 1 - 05/16/18||
(May 16, 2018)
This article is no longer available,but here are some related topics.
AES Attendees,Medicine,Disease,Technology,Surgery,Medication,Childrens Health,Science,Medical Technology,Medical,Genetics,Children,Other,
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved